Pacific Pharmaceuticals · Small Molecule · Small Molecule
minoxidil is a small molecule developed by Pacific Pharmaceuticals. It is approved for therapeutic indications.
| Brand Names | Headway, minoxidil, Pacific |
| Company | Pacific Pharmaceuticals |
| Drug Class | Small Molecule |
| Status | Approved |
minoxidil is developed for 2 unique indications across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Skin and subcutaneous tissue disorders | Skin disorder | ✓ Approved |
| Skin and subcutaneous tissue disorders | Dermatosis | ✓ Approved |
Baker Gabrielle G, Han Nguyen Megan Thuy MT, Greene Rachel K RK, Hirpara Milan M et al.
de Santana Santos Ingrid Araujo IA, Medeiros-Souza Patricia P, Gratieri Tais T, Gelfuso Guilherme G et al.
Minoxidil remains a cornerstone of pharmacological therapy for androgenetic alopecia (AGA), yet conventional topical formulations are constrained by pharmaceutical, biological, and patient-related limitations that compromise their real-world efficacy. Meanwhile, the rapid adoption of low-dose oral minoxidil (LDOM) is reshaping the therapeutic landscape and challenging the traditional paradigm of topical drug delivery. This Perspective critically examines the limitations of conventional topical minoxidil, recent advances in topical drug-delivery technologies, and the resurgence of LDOM, including emerging clinical evidence and ongoing development programs. Pharmaceutical innovations aimed at optimizing oral therapy, including individualized dosing, alternative administration routes, personalized manufacturing, and combination strategies, are also discussed. Expert opinion: Future innovation should move beyond the pursuit of a universally superior minoxidil formulation toward matching the appropriate route, formulation, dose, and therapeutic strategy to individual patients. Rather than competing alternatives, topical and oral minoxidil may become complementary components of a precision-treatment framework integrating pharmaceutical technology, predictive biomarkers, pharmacogenetics, artificial intelligence, and digital health. We propose that this transition toward precision minoxidil therapy may define the next generation of AGA management.
Zhao Ziyi Z, Huang Xiaoxiao X, Huang Lining L, Xing Hui H et al.
Androgenetic alopecia (AGA) is a common hair loss disorder caused by genetic susceptibility and androgen-driven follicular miniaturization. Current FDA-approved therapies, including finasteride and minoxidil, are limited by adverse effects. Here, we developed a hyaluronic acid-based liposomal transdermal delivery system loaded with L-arginine (HL@L-Arg) to enhance cutaneous delivery and promote endogenous nitric oxide (NO) production through nitric oxide synthase. Transcriptomic analysis indicated significant changes in pathways related to inflammatory responses, Wnt signaling, and steroid hormone biosynthesis. Mechanistically, HL@L-Arg inhibited 5α-reductase activity and reduced dihydrotestosterone (DHT) production while promoting endogenous NO generation. In an AGA mouse model, HL@L-Arg reduced TNF-α, IL-6, and androgen receptor (AR) expression, increased VEGF and Ki67 levels, and markedly promoted hair regeneration. Collectively, transdermal L-Arg delivery represents a promising endogenous NO-based therapeutic strategy for AGA through DHT suppression, regulation of the follicular microenvironment, and anti-inflammatory activity.
Lo Amy Ws AW, Leung Sheona Sn SS, Wong Cindy Ls CL, Lai Jessica J et al.
Persistent chemotherapy-induced alopecia (pCIA) is defined as incomplete hair growth ≥6 months after chemotherapy completion. This scoping review aimed to identify gaps for future research by mapping pCIA's incidence, risk factors, quality-of-life (QoL) impacts, presentation, prevention, and management. Thirty-nine articles were included. The most common study type was case reports (12/39, 30.8%). Only 2/39 (5.1%) were randomized controlled trials (RCTs). Most studies (27/39, 69.2%) reported pCIA in patients with breast cancer. Alkylating agents, taxanes, and anthracyclines were most frequently reported to be associated with pCIA. All six studies that evaluated QoL reported that pCIA negatively affected patients' psychological, functional, and social well-being. Scalp cooling was the only intervention shown to prevent pCIA in four studies. Twenty-one studies reported on interventions for the management of pCIA. Topical minoxidil was reported to improve pCIA in 7 out of 12 studies (58.3%). Low-dose oral minoxidil demonstrated benefit in 7 out of 7 studies (100%). pCIA's incidence and risk factors should be prospectively evaluated across cancer types and chemotherapeutic agents. Given pCIA's significant QoL impacts, RCTs should be conducted to investigate existing and emerging interventions for its prevention and management, and to consider including these interventions in the standard of care.
Piraccini Bianca Maria BM, Gupta Aditya K AK, Cedirian Stephano S, Rapparini Luca L et al.
Female pattern hair loss (FPHL), characterized by progressive follicular miniaturization, is the most common cause of hair thinning in women and increases in prevalence after menopause. While topical minoxidil is approved for FPHL, clinical response is variable. Oral finasteride is used off label in postmenopausal women but raises concerns regarding systemic adverse effects. Topical finasteride may represent an alternative with reduced systemic exposure. A retrospective observational study was conducted in 26 postmenopausal women with FPHL who were treated with topical finasteride 0.25% monotherapy for 52 weeks. Clinical and trichoscopic images obtained at baseline and Week 52 were used to assess changes in hair density, hair thickness, and the terminal-to-vellus hair ratio in predefined target areas in frontal or vertex regions. Patient-reported tolerability and compliance, as well as patient- and clinician-reported effectiveness, were assessed using 3-point ordinal scales. Mean hair density increased from 149.48 ± 34.32 to 172.84 ± 35.29 hairs/cm2 (p < 0.001). Hair thickness increased from 40.42 ± 7.15 μm to 51.04 ± 9.28 μm (p < 0.001), and terminal-to-vellus hair ratio increased from 1.04 ± 0.61 to 1.56 ± 0.64 (p < 0.001). Subjective patient and clinician assessments indicated good-to-excellent effectiveness. No adverse events were recorded; tolerability and compliance were rated highly by patients. Topical finasteride 0.25% monotherapy was associated with significant improvements in hair density and thickness, alongside favorable reported tolerability and compliance. These findings provide preliminary real-world observational data regarding topical finasteride use in the underserved population of postmenopausal women with FPHL.
Iimura Yohei Y, Yokota Tomoya T, Hashimoto Hironobu H, Kuroda Seiichiro S
Chemotherapy-induced alopecia (CIA) is common, distressing, and markedly impairs patients' quality of life. Although scalp cooling is the only approved preventive strategy, its effectiveness and accessibility remain limited. Therefore, alternative pharmacologic approaches, such as minoxidil and prostaglandin analogs, have been explored. This scoping review aimed to explore the available evidence on minoxidil's efficacy and safety and the potential role of prostaglandin analogs in alopecia. PubMed, Cochrane Library, Medical Online, and Ichushi-Web were comprehensively searched from inception to February 2026. Studies evaluating minoxidil in CIA and prostaglandin analogs in any alopecia type were included. Case reports, case series, and non-human studies were excluded. Seven studies were included. Five studies evaluated minoxidil in CIA, including two randomized controlled trials and three retrospective studies on prophylactic and therapeutic use, respectively. Prophylactic topical minoxidil did not markedly prevent CIA but was associated with earlier hair regrowth. In contrast, therapeutic use-particularly of oral minoxidil-improved hair density and treatment response. No serious adverse events were reported, although cardiovascular effects remain a concern with oral formulations. Two randomized controlled trials evaluated prostaglandin analogs in non-chemotherapy-related alopecia and showed markedly improved hair density and regrowth. However, no study directly assessed their efficacy in CIA. Minoxidil may be beneficial for hair regrowth in CIA but shows limited preventive efficacy. Prostaglandin analogs are promising but untested in this setting. Future studies should evaluate their role, particularly in combination with minoxidil, to address the current evidence gap and improve outcomes for patients with CIA.
+2982 more articles available with a free account
Sign up free to view all articles →